Um dos principais objetivos do Life4me+ - é prevenir novos casos de HIV e outras ISTs, hepatite C e tuberculose.

O aplicativo ajuda a estabelecer uma comunicação anônima entre médicos e pessoas soropositivas. A App permite que você organize convenientemente o seu horário de toma dos medicamentos e defina de uma forma personalizada os lembretes.

Todas as notícias / Dezembro 2016

Arquivo

✕

27 dezembro 2016

9004

Cameroon: 50 people were convicted of homosexuality between 2010 and 2014

Cameroon: 50 people were convicted of homosexuality between 2010 and 2014

Cameroon is still prosecutes people for being gay more aggressively than almost any other nation in the world. According to data collected by The Cameroonian Foundation for AIDS, at least 50 people in Cameroon were convicted of homosexuality between 2010 and 2014 for acts ...

26 dezembro 2016

8880

Sweden, Denmark and Norway to increase their contribution to UNAIDS next year

Sweden, Denmark and Norway to increase their contribution to UNAIDS next year

UNAIDS has published a press release in which welcomes new funding commitments from 3 Nordic countries for 2017.

25 dezembro 2016

8206

UK: 40% drop in new HIV infections

UK: 40% drop in new HIV infections

The largest sexual health clinic in the UK has reported a dramatic drop in the number of people they have diagnosed with HIV this year.

22 dezembro 2016

8369

Janssen Sciences: Investigational two-drug HIV regimen showed positive results

Janssen Sciences: Investigational two-drug HIV regimen showed positive results

Janssen Sciences Ireland UC (Janssen) announced the results from first phase III studies of investigational two-drug HIV treatment regimen. Two Phase III studies were designed to evaluate the safety and efficacy of switching virologically suppressed patients from a three ...

21 dezembro 2016

9362

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

Study: Use of direct-acting antivirals for the treatment of Hepatitis C virus infection, which contain sofosbuvir can lead to Hepatitis B reactivation in the body, as well as to interact with HIV drug tenofovir disoproxil.

21 dezembro 2016

10380

GSK to test injectable drug for PrEP

GSK to test injectable drug for PrEP

GlaxoSmithKline had started a large study to test an experimental long-acting injection for preventing of HIV infection. The drug cabotegravir, an injectable medication, which if effective might become an alternative to Truvada.

21 dezembro 2016

9622

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

Study: Drugs for HIV and Hepatitis C treatment can cause side effects when used together

According to a study published by University of Rhode Island pharmacy professor and a graduate student in the Journal of Hepatology, use of direct-acting antivirals for the treatment of Hepatitis C virus infection , such as Sovaldi, Harvoni and Epclusa, which contain sofosbuvir ...

20 dezembro 2016

10000

Dolutegravir quickly reduces viral load in semen

Dolutegravir quickly reduces viral load in semen

According to the new study published in the Journal of Infectious Diseases, dolutegravir (Tivicay) is able to dramatically reduce the viral load in semen. Semen is thought to be a reservoir of the virus and other antiviral drugs have difficult time reaching this area. It ...

20 dezembro 2016

8174

Study: sex-race health disparities in the occurrence of chronic diseases associated with ageing

Study: sex-race health disparities in the occurrence of chronic diseases associated with ageing

A group of researchers from the United States have published the results of a study regarding ART-treated people and sex-race disparities in the occurrence of chronic diseases associated with ageing. The study was published in the online edition of Clinical Infectious Diseases. ...

19 dezembro 2016

8398

Ibalizumab might be the answer for patients with drug resistance

Ibalizumab might be the answer for patients with drug resistance

According to the results from a Phase 3 trial published in October, an experimental injectable drug, ibalizumab, might be an option for patients struggling with drug resistance. Drug resistant strains are now a major threat to effective HIV treatment worldwide. Patients ...

1 2 3...5